MCID: CCN001
MIFTS: 51

Cocaine Dependence

Categories: Mental diseases

Aliases & Classifications for Cocaine Dependence

Summaries for Cocaine Dependence

Disease Ontology : 12 A drug dependence that is a psychological dependency on the regular use of cocaine.

MalaCards based summary : Cocaine Dependence is related to psychotic disorder and antisocial personality disorder. An important gene associated with Cocaine Dependence is DRD2 (Dopamine Receptor D2), and among its related pathways/superpathways are Circadian entrainment and Peptide ligand-binding receptors. The drugs Dopamine and Cocaine have been mentioned in the context of this disorder. Affiliated tissues include brain, heart and cortex, and related phenotypes are behavior/neurological and homeostasis/metabolism

Wikipedia : 76 Cocaine dependence is a psychological desire to use cocaine regularly. Cocaine overdose may result in... more...

Related Diseases for Cocaine Dependence

Diseases related to Cocaine Dependence via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 84)
# Related Disease Score Top Affiliating Genes
1 psychotic disorder 31.1 DRD2 DRD3 SLC6A3 SLC6A4
2 antisocial personality disorder 30.8 DRD2 SLC6A3 SLC6A4
3 personality disorder 30.5 DRD2 DRD3 SLC6A3 SLC6A4
4 alexithymia 30.2 DRD2 SLC6A4
5 pathological gambling 30.1 DRD2 DRD3 SLC6A3 SLC6A4
6 alcohol abuse 30.0 DRD2 DRD3 SLC6A4
7 schizoaffective disorder 30.0 DRD2 DRD3 SLC6A4
8 cocaine abuse 29.8 DBH DRD2 SLC6A3 SLC6A4
9 bipolar disorder 29.6 DBH DRD2 DRD3 SLC6A3 SLC6A4
10 schizophrenia 29.6 DBH DRD2 DRD3 SLC6A3 SLC6A4
11 mood disorder 29.4 DRD2 DRD3 POMC SLC6A4
12 cannabis abuse 29.1 CHRNA3 CHRNB3
13 smoking as a quantitative trait locus 3 29.1 CHRNA3 CHRNA5
14 heroin dependence 29.0 DRD2 OPRD1 OPRM1 PDYN
15 major depressive disorder 29.0 DRD2 DRD3 POMC SLC6A3 SLC6A4
16 attention deficit-hyperactivity disorder 28.9 DBH DRD2 DRD3 OPRM1 SLC6A3 SLC6A4
17 opioid addiction 28.7 DRD2 OPRD1 OPRK1 OPRM1
18 tobacco addiction 26.5 CHRNA3 CHRNA5 CHRNB3 DRD2 OPRM1 SLC6A3
19 alcohol dependence 25.9 DBH DRD2 DRD3 OPRD1 OPRK1 OPRM1
20 drug dependence 25.4 CHRNB3 DRD2 DRD3 OPRD1 OPRK1 OPRM1
21 substance dependence 24.2 CHRNA3 CHRNA5 DRD2 DRD3 OPRD1 OPRK1
22 cocaine intoxication 11.0
23 polysubstance abuse 10.7 DRD2 DRD3
24 delusional disorder 10.7 DRD2 DRD3
25 tardive dyskinesia 10.7 DRD2 DRD3
26 impulse control disorder 10.7 DRD2 DRD3
27 obsessive-compulsive personality disorder 10.7 DRD3 SLC6A4
28 social phobia 10.6 DRD2 SLC6A4
29 striatonigral degeneration 10.6 DRD2 SLC6A3
30 premature ejaculation 10.6 SLC6A3 SLC6A4
31 periodic limb movement disorder 10.6 DRD2 SLC6A4
32 tic disorder 10.5 DRD2 SLC6A3
33 alcohol-induced mental disorder 10.5 DRD2 SLC6A3 SLC6A4
34 alcoholic psychosis 10.5 DRD2 SLC6A3 SLC6A4
35 cutaneous solitary mastocytoma 10.5 PDYN POMC
36 functioning pituitary adenoma 10.5 DRD2 POMC
37 movement disease 10.4 DRD2 DRD3 SLC6A3
38 migraine without aura 10.4 DRD2 DRD3 SLC6A4
39 bruxism 10.4 DRD2 SLC6A4
40 phobic disorder 10.4 OPRK1 SLC6A4
41 stuttering 10.4 DBH DRD2 SLC6A3
42 multiple system atrophy 1 10.4 DBH DRD2 SLC6A3
43 gilles de la tourette syndrome 10.4 DBH DRD2 SLC6A3
44 opioid abuse 10.3 DRD2 OPRM1 PDYN
45 retrograde amnesia 10.3 PDYN POMC SLC6A4
46 depression 10.3
47 narcolepsy 10.2 DRD2 PDYN SLC6A3
48 obsessive-compulsive disorder 10.1 DRD2 DRD3 SLC6A3 SLC6A4
49 withdrawal disorder 10.1 OPRM1 PDYN POMC
50 oppositional defiant disorder 10.1 DBH DRD2 SLC6A3 SLC6A4

Graphical network of the top 20 diseases related to Cocaine Dependence:



Diseases related to Cocaine Dependence

Symptoms & Phenotypes for Cocaine Dependence

MGI Mouse Phenotypes related to Cocaine Dependence:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.25 DRD2 PDYN DRD3 CHRNA3 OPRD1 CHRNA5
2 homeostasis/metabolism MP:0005376 10 OPRM1 DRD2 PDYN DRD3 CHRNA3 OPRD1
3 growth/size/body region MP:0005378 9.97 OPRM1 DRD2 DRD3 CHRNA3 DBH SLC6A4
4 adipose tissue MP:0005375 9.93 OPRM1 DRD2 PDYN DRD3 DBH POMC
5 endocrine/exocrine gland MP:0005379 9.91 DBH OPRM1 DRD2 OPRK1 SLC6A3 SLC6A4
6 digestive/alimentary MP:0005381 9.88 OPRM1 DRD2 DRD3 CHRNA3 OPRK1 PDYN
7 integument MP:0010771 9.81 OPRM1 DRD2 PDYN OPRD1 OPRK1 DBH
8 nervous system MP:0003631 9.73 DRD2 PDYN DRD3 CHRNA3 OPRD1 CHRNA5
9 no phenotypic analysis MP:0003012 9.1 OPRM1 DRD2 CHRNA3 OPRD1 PDYN POMC

Drugs & Therapeutics for Cocaine Dependence

Drugs for Cocaine Dependence (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 325)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 51-61-6, 62-31-7 681
2
Cocaine Approved, Illicit Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 50-36-2 5760 446220
3
Modafinil Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 68693-11-8 4236
4
Risperidone Approved, Investigational Phase 4,Phase 2,Phase 1,Not Applicable 106266-06-2 5073
5
Ethanol Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 64-17-5 702
6
Biperiden Approved, Investigational Phase 4,Phase 3,Phase 2 514-65-8 2381
7
Armodafinil Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 112111-43-0
8
Carbamazepine Approved, Investigational Phase 4,Phase 2 298-46-4 2554
9
Lamotrigine Approved, Investigational Phase 4,Phase 2 84057-84-1 3878
10
Amphetamine Approved, Illicit, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 300-62-9 5826 3007
11
Disulfiram Approved Phase 4,Phase 2,Phase 1 97-77-8 3117
12
Methamphetamine Approved, Illicit Phase 4,Not Applicable 537-46-2 10836
13
Acetylcysteine Approved, Investigational Phase 4,Phase 2,Phase 1,Early Phase 1 616-91-1 12035
14
Azacitidine Approved, Investigational Phase 4 320-67-2 9444
15
Caffeine Approved, Nutraceutical Phase 4,Phase 2,Phase 3,Phase 1 58-08-2 2519
16
Choline Approved, Nutraceutical Phase 4,Phase 3,Not Applicable 62-49-7 305
17
Glutamic Acid Approved, Nutraceutical Phase 4,Phase 1,Early Phase 1 56-86-0 33032
18 Dopamine agonists Phase 4,Phase 2,Phase 3,Phase 1
19 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
20 Adrenergic Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
21 Central Nervous System Stimulants Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
22 Cholinergic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
23 Muscarinic Antagonists Phase 4,Phase 3,Phase 2,Phase 1
24 Cholinergic Antagonists Phase 4,Phase 3,Phase 2,Phase 1
25 Serotonin Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
26 Serotonin Antagonists Phase 4,Phase 2,Phase 1,Not Applicable
27 Gastrointestinal Agents Phase 4,Phase 2,Phase 1,Not Applicable
28 Sodium Channel Blockers Phase 4,Phase 2,Phase 1
29 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
30 Neurotransmitter Uptake Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
31 Cytochrome P-450 CYP3A Inducers Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
32 Anesthetics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
33 Anesthetics, Local Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
34 Tranquilizing Agents Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1
35 Diuretics, Potassium Sparing Phase 4,Phase 2,Phase 1
36 Parasympatholytics Phase 4,Phase 3,Phase 2,Phase 1
37 Dopamine Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
38 Vasoconstrictor Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
39 Dopamine Antagonists Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1
40 Dopamine Uptake Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
41 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
42 Wakefulness-Promoting Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
43 Phosphodiesterase Inhibitors Phase 4,Phase 2,Phase 3,Phase 1
44 Anticonvulsants Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
45 Protective Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
46 Antiparkinson Agents Phase 4,Phase 2,Phase 3,Phase 1
47 Antipsychotic Agents Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1
48 Purinergic P1 Receptor Antagonists Phase 4,Phase 2,Phase 3,Phase 1
49 Psychotropic Drugs Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
50 Autonomic Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1

Interventional clinical trials:

(show top 50) (show all 337)
# Name Status NCT ID Phase Drugs
1 Efficacy of Caffeine, With and Without Biperiden, as a Maintenance Treatment for Cocaine Dependence Unknown status NCT00495183 Phase 4 caffeine;Biperiden;Placebo
2 Citicoline for Bipolar 1 Disorder and Cocaine Dependence Completed NCT00619723 Phase 4 Citicoline;Placebo
3 An Add-On Trial of Quetiapine in Patients With Bipolar Disorder and Cocaine Dependence Completed NCT00223210 Phase 4 Quetiapine;PLacebo
4 Neurobiological Adaptations and Pharmacological Interventions in Cocaine Addiction Completed NCT02626494 Phase 4 N-Acetylcystein;Placebo
5 Lamotrigine add-on Therapy for Bipolar Disorder and Cocaine Dependency Completed NCT00280293 Phase 4 Lamotrigine;Placebo
6 Pathophysiological Subtyping of Abnormalities in Cocaine Dependence - 9 Completed NCT00015275 Phase 4
7 Quetiapine for Cocaine Use and Cravings Completed NCT00232336 Phase 4 quetiapine
8 Pharmacotherapy and Intensive Treatment - 2 Completed NCT00000218 Phase 4 Carbamazepine
9 Effects of Modafinil in Methamphetamine Dependence Completed NCT00751023 Phase 4 Modafinil;Placebo
10 Seroquel Therapy for Substance Use Disorders Comorbid With Schizophrenia Completed NCT00208143 Phase 4 Quetiapine;Risperidone
11 Effect of N-acetylcysteine on Alcohol and Cocaine Use Disorders: A Double-Blind Randomized Controlled Trial. Recruiting NCT03018236 Phase 4 Alcohol N-acetylcysteine;Alcohol Placebo;Cocaine N-acetylcysteine;Cocaine Placebo
12 A PET Exploration of the Mechanism of Action of Dopamine Beta-hydroxylase Inhibition in Cocaine Addicts Withdrawn NCT02134002 Phase 4 Disulfiram;Placebo
13 Effectiveness of Topiramate in Treating Cocaine Dependent Individuals - 1 Unknown status NCT00249691 Phase 3 Topiramate + Cognitive Behavioral Therapy;Placebo + Cognitive Behavioral Therapy
14 Novel Pharmacotherapy for Dual Dependence Unknown status NCT00448825 Phase 3 Topiramate + Cognitive Behavioral Therapy;Placebo + Cognitive Behavioral Therapy
15 Multicenter Trial of Combined Pharmacotherapy to Treat Cocaine Dependence Completed NCT01811940 Phase 2, Phase 3 Adderall-ER;Topiramate
16 Imaging the Neurobiology of Behavioral and Medication Treatment for Cocaine Dependence Completed NCT01468012 Phase 2, Phase 3 levodopa carbidopa and entacapone (LCE);Placebo
17 Study of Adderall-XR for the Treatment of Adult Attention Deficit Hyperactivity Disorder and Cocaine Dependence Completed NCT00553319 Phase 2, Phase 3 Placebo;Adderall-XR;Adderall-XR
18 Selegiline Transdermal System for the Treatment of Cocaine Dependence - 1 Completed NCT00032929 Phase 3 Selegiline
19 Brain Imaging Study of the Effects of Modafinil in Cocaine Addiction Completed NCT00701532 Phase 3 Modafinil and PET (brain imaging);placebo
20 Naltrexone in Two Models of Psychosocial Treatments for Cocaine and Alcohol Dependence Completed NCT00167232 Phase 3 Naltrexone
21 Dose Response Trial of Pergolide for Cocaine Dependence - 1 Completed NCT00000248 Phase 3 Pergolide
22 Investigation of Mifepristone (RU486) on Stress Sensitivity and Relapse Prevention in Cocaine Dependent Patients Completed NCT01134198 Phase 2, Phase 3 Mifepristone;placebo
23 Naltrexone in Two Models of Psychosocial Treatments for Cocaine and Alcohol Dependence - 1 Completed NCT00218660 Phase 3 Naltrexone;Placebo
24 Vigabatrin for the Treatment of Cocaine Dependency Completed NCT01281202 Phase 2, Phase 3 Vigabatrin;Matching Placebo
25 Adaptive Treatment for Alcohol and Cocaine Dependence Completed NCT01032135 Phase 2, Phase 3 medication management
26 Cocaine Use Reduction With Buprenorphine Completed NCT01402492 Phase 2, Phase 3 Buprenorphine + Naltrexone;Placebo + Naltrexone
27 Investigation of Intranasal Oxytocin on Relapse Risk in Cocaine-dependent Patients. Completed NCT02255357 Phase 2, Phase 3 Placebo;Intranasal Oxytocin
28 Cocaine/Crack and Reduction of Compulsion With Biperiden Completed NCT01251393 Phase 3 Biperiden;Placebo
29 Clinical Neurobiology of Serotonin and Addiction Completed NCT00732901 Phase 2, Phase 3 Escitalopram;Placebo
30 Progesterone Treatment for Cocaine-dependent Women: A Pilot Study Completed NCT00632099 Phase 2, Phase 3 Oral micronized progesterone;Placebo
31 Efficacy of Caffeine, With and Without Biperiden, in the Detoxification of Cocaine Dependent Patients Completed NCT00495092 Phase 2, Phase 3 Caffeine;Biperiden;Placebo
32 Effect of Nefazodone on Relapse in Females With Cocaine Abuse - 10 Completed NCT00000293 Phase 3 Nefazodone
33 Smoking-Cessation and Stimulant Treatment (S-CAST) Completed NCT01077024 Phase 3
34 Treatment of Adult Attention Deficit Hyperactivity Disorder (ADHD) in Methadone Patients - 1 Completed NCT00061087 Phase 2, Phase 3 Methylphenidate;Bupropion
35 Trial of Citicoline Therapy in Patients With Mania or Hypomania and Cocaine Abuse/Dependence Completed NCT00223236 Phase 3 Citicoline;Placebo
36 Bupropion-Enhanced Contingency Management (CM) for Cocaine Dependence Recruiting NCT02111798 Phase 2, Phase 3 Bupropion XL;placebo
37 Change the Cycle: An RCT to Prevent Injection Initiation Active, not recruiting NCT02774954 Phase 3
38 Randomised Placebo-Controlled Trial of Modafinil for Cocaine Dependence Unknown status NCT00123383 Phase 2 Modafinil
39 Study of the Effect of Magnetic Stimulation Repetitive Transcranial on Impulsivity in Cocaine Dependence Unknown status NCT01397266 Phase 2
40 A Double-Blind, Controlled Study of Aripiprazole in Co-Morbid Schizophrenia and Cocaine Dependence Unknown status NCT00737256 Phase 2 Aripiprazole;Perphenazine
41 A Pilot Study of Candesartan as a Treatment for Cocaine Dependence Unknown status NCT01938664 Phase 2 Candesartan;Placebo
42 Treating Cocaine Abuse: A Behavioral Approach Unknown status NCT01822327 Phase 2
43 Effects of Repeated Transcranial Magnetic Stimulation (rTMS) on the Treatment of Cocaine Addicted Patients Unknown status NCT01259362 Phase 2
44 Repetitive Transcranial Magnetic Stimulation in Symptoms of Attention Deficit Hyperactivity Disorder and Cognitive Function In Cocaine Addicts Unknown status NCT01593982 Phase 2
45 Lidocaine Infusion as a Treatment for Cocaine Relapse and Craving Unknown status NCT01929343 Phase 2 lidocaine following cue-induced craving;lidocaine following neutral stimulus;saline
46 Psychopharmacology for Cocaine Dependence - Buspirone Completed NCT01267292 Phase 2 Buspirone;Placebo for Buspirone;Methylphenidate;Placebo for Methylphenidate
47 Brain Function and Structure in Cocaine Dependence Completed NCT02080832 Phase 2 Citalopram;Placebo
48 Pharmacogenetics of Doxazosin for Cocaine Dependence Completed NCT01145183 Phase 2 Doxazosin;Placebo
49 Open-Label Pilot Study of Lisdexamfetamine for Cocaine Dependence Completed NCT01486810 Phase 1, Phase 2 Lisdexamfetamine
50 Citalopram for Cocaine Dependence Completed NCT01535573 Phase 2 Citalopram;Citalopram;Placebo

Search NIH Clinical Center for Cocaine Dependence

Genetic Tests for Cocaine Dependence

Anatomical Context for Cocaine Dependence

MalaCards organs/tissues related to Cocaine Dependence:

41
Brain, Heart, Cortex, Prefrontal Cortex, Pituitary, Testes, Prostate

Publications for Cocaine Dependence

Articles related to Cocaine Dependence:

(show top 50) (show all 624)
# Title Authors Year
1
Neurostimulation techniques in the treatment of cocaine dependence: A review of the literature. ( 28822321 )
2018
2
How treatment improvement in ADHD and cocaine dependence are related to one another: A secondary analysis. ( 29775957 )
2018
3
Attentional bias toward alcohol stimuli as a predictor of treatment retention in cocaine dependence and alcohol user patients. ( 29136565 )
2018
4
Ventral striatal dysfunction in cocaine dependence - difference mapping for subregional resting state functional connectivity. ( 29915214 )
2018
5
Effect of continuing care for people with cocaine dependence on criminal justice sentences. ( 29460440 )
2018
6
Is Ayahuasca an Option for the Treatment of Crack Cocaine Dependence? ( 29608428 )
2018
7
Drug Stroop: Mechanisms of response to computerized cognitive behavioral therapy for cocaine dependence in a randomized clinical trial. ( 29258028 )
2018
8
Dynamic network dysfunction in cocaine dependence: Graph theoretical metrics and stop signal reaction time. ( 29876265 )
2018
9
Repeated Administration of Opra Kappa (LY2456302), a Novel, Short-Acting, Selective KOP-r Antagonist, in Persons with and without Cocaine Dependence. ( 29422497 )
2018
10
Pharmacogenetics of Dopamine I^-Hydroxylase in cocaine dependence therapy with doxazosin. ( 29498170 )
2018
11
Comparing pharmacological treatments for cocaine dependence: Incorporation of methods for enhancing generalizability in meta-analytic studies. ( 29464791 )
2018
12
Galantamine and Computerized Cognitive Behavioral Therapy for Cocaine Dependence: A Randomized Clinical Trial. ( 29286595 )
2017
13
Reply to: kynurenic acid and alcohol and cocaine dependence: novel effects and multiple mechanisms? ( 27896378 )
2017
14
Functional neural changes following behavioral therapies and disulfiram for cocaine dependence. ( 28714728 )
2017
15
Cocaine dependence modulates the effect of HIV infection on brain activation during intertemporal decision making. ( 28711810 )
2017
16
Modafinil Treatment of Cocaine Dependence: A Systematic Review and Meta-Analysis. ( 28350194 )
2017
17
White Matter Changes in HIV+ Women with a History of Cocaine Dependence. ( 29163330 )
2017
18
Kynurenic acid and alcohol and cocaine dependence: novel effects and multiple mechanisms? ( 27885412 )
2017
19
Repeated Administration of Opra Kappa (LY2456302), a Novel, Short-Acting, Selective KOP-r Antagonist, in Persons with and without Cocaine Dependence. ( 28857070 )
2017
20
A comparison of psychotic symptoms in subjects with methamphetamine versus cocaine dependence. ( 28190084 )
2017
21
Sex differences in guanfacine effects on stress-induced stroop performance in cocaine dependence. ( 28823835 )
2017
22
A Novel Therapy for cocaine dependence during abstinence: A randomized clinical trial. ( 28894547 )
2017
23
Cocaine dependence does not contribute substantially to white matter abnormalities in HIV infection. ( 28251596 )
2017
24
Late Reduction of Cocaine Cravings in a Randomized, Double-Blind Trial of Aripiprazole vs Perphenazine in Schizophrenia and Comorbid Cocaine Dependence. ( 28984746 )
2017
25
Netrin G1: its downregulation in the nucleus accumbens of cocaine-conditioned mice and genetic association in human cocaine dependence. ( 28074533 )
2017
26
Assessing the effects of cocaine dependence and pathological gambling using group-wise sparse representation of natural stimulus FMRI data. ( 27704410 )
2016
27
Efficacy of topiramate in the treatment of crack cocaine dependence: a double-blind, randomized, placebo-controlled trial. ( 27046312 )
2016
28
Cocaine dependence and thalamic functional connectivity: a multivariate pattern analysis. ( 27556009 )
2016
29
Effect of Continuing Care for Cocaine Dependence on HIV Sex-Risk Behaviors. ( 27224980 )
2016
30
Psychiatric comorbidity in a sample of cocaine-dependent outpatients seen in the Community of Madrid drug addiction care network. ( 26990385 )
2016
31
A randomized factorial trial of disulfiram and contingency management to enhance cognitive behavioral therapy for cocaine dependence. ( 26817621 )
2016
32
Neurofunctional Reward Processing Changes in Cocaine Dependence During Recovery. ( 26792441 )
2016
33
Modafinil and sleep architecture in an inpatient-outpatient treatment study of cocaine dependence. ( 26777774 )
2016
34
Psychostimulant drugs for cocaine dependence. ( 27670244 )
2016
35
Clinical differences between cocaine-dependent patients with and without antisocial personality disorder. ( 27839828 )
2016
36
A delta-opioid receptor genetic variant is associated with abstinence prior to and during cocaine dependence treatment. ( 27449273 )
2016
37
Just showing up is not enough: Homework adherence and outcome in cognitive-behavioral therapy for cocaine dependence. ( 27454780 )
2016
38
Attenuated neural response to emotional cues in cocaine-dependence: a preliminary analysis of gender differences. ( 27441590 )
2016
39
Mixed-amphetamine salts increase abstinence from marijuana in patients with co-occurring attention-deficit/hyperactivity disorder and cocaine dependence. ( 28051838 )
2016
40
Successful classification of cocaine dependence using brain imaging: a generalizable machine learning approach. ( 27766943 )
2016
41
A Highly Polymorphic Copy Number Variant in the NSF Gene is Associated with Cocaine Dependence. ( 27498889 )
2016
42
Topiramate for Cocaine Dependence: A Systematic Review and Meta-Analysis of Randomized Control Trials. ( 26826006 )
2016
43
Subcortical grey matter alterations in cocaine dependent individuals with substance-induced psychosis compared to non-psychotic cocaine users. ( 27499362 )
2016
44
Psychotic symptoms associated with the use of dopaminergic drugs, in patients with cocaine dependence or abuse. ( 27009114 )
2016
45
Crack-cocaine dependence and aging: effects on working memory. ( 27111700 )
2016
46
Buprenorphinea88+a88Naloxone plus Naltrexone for the Treatment of Cocaine Dependence: The Cocaine Use Reduction with Buprenorphine (CURB) Study. ( 26948856 )
2016
47
Antipsychotic medications for cocaine dependence. ( 26992929 )
2016
48
Utility of Machine-Learning Approaches to Identify Behavioral Markers for Substance Use Disorders: Impulsivity Dimensions as Predictors of Current Cocaine Dependence. ( 27014100 )
2016
49
Cocaine-induced Psychosis and Brain-derived Neurothrophic Factor in Patients with Cocaine Dependence: Report of Two Cases. ( 26792050 )
2016
50
Characterization of white matter integrity deficits in cocaine-dependent individuals with substance-induced psychosis compared with non-psychotic cocaine users. ( 26833821 )
2016

Variations for Cocaine Dependence

Expression for Cocaine Dependence

Search GEO for disease gene expression data for Cocaine Dependence.

Pathways for Cocaine Dependence

Pathways related to Cocaine Dependence according to GeneCards Suite gene sharing:

(show all 11)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.64 CHRNA3 DRD2 DRD3 OPRM1 SLC6A3
2
Show member pathways
12.59 CHRNA3 CHRNA5 CHRNB3 DRD2 DRD3 OPRD1
3
Show member pathways
12.57 CHRNA3 CHRNA5 CHRNB3 SLC6A3 SLC6A4
5
Show member pathways
11.68 DRD2 PDYN SLC6A3
6 11.64 OPRD1 OPRM1 POMC
7
Show member pathways
11.36 CHRNA3 CHRNA5 CHRNB3
8
Show member pathways
11.27 CHRNA3 CHRNA5 DRD2 DRD3
9
Show member pathways
10.97 DBH SLC6A3 SLC6A4
10
Show member pathways
10.89 SLC6A3 SLC6A4
11 10.8 DRD2 DRD3

GO Terms for Cocaine Dependence

Cellular components related to Cocaine Dependence according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 synapse GO:0045202 9.83 CHRNA3 CHRNA5 CHRNB3 OPRK1
2 neuronal cell body GO:0043025 9.8 CHRNA3 OPRK1 PDYN SLC6A3
3 dendrite GO:0030425 9.77 CHRNA3 DRD2 OPRK1 OPRM1 PDYN
4 postsynaptic membrane GO:0045211 9.76 CHRNA3 CHRNA5 CHRNB3 OPRD1
5 membrane raft GO:0045121 9.73 OPRD1 OPRM1 SLC6A3 SLC6A4
6 perikaryon GO:0043204 9.65 DRD2 OPRK1 OPRM1
7 integral component of plasma membrane GO:0005887 9.65 CHRNA3 CHRNA5 CHRNB3 DRD2 DRD3 OPRD1
8 dendrite membrane GO:0032590 9.51 OPRD1 OPRM1
9 axon terminus GO:0043679 9.46 DRD2 OPRD1 OPRK1 PDYN
10 acetylcholine-gated channel complex GO:0005892 9.43 CHRNA3 CHRNA5 CHRNB3
11 neuron projection GO:0043005 9.23 CHRNA3 CHRNA5 CHRNB3 OPRD1 OPRK1 OPRM1
12 membrane GO:0016020 10.28 CHRNA3 CHRNA5 CHRNB3 DBH DRD2 DRD3
13 integral component of membrane GO:0016021 10.14 CHRNA3 CHRNA5 CHRNB3 DBH DRD2 DRD3
14 plasma membrane GO:0005886 10.06 CHRNA3 CHRNA5 CHRNB3 DRD2 DRD3 OPRD1

Biological processes related to Cocaine Dependence according to GeneCards Suite gene sharing:

(show top 50) (show all 60)
# Name GO ID Score Top Affiliating Genes
1 response to drug GO:0042493 9.98 DRD2 DRD3 SLC6A3 SLC6A4
2 regulation of membrane potential GO:0042391 9.88 CHRNA3 CHRNA5 CHRNB3
3 phospholipase C-activating G-protein coupled receptor signaling pathway GO:0007200 9.83 OPRD1 OPRK1 OPRM1
4 G-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger GO:0007187 9.83 OPRD1 OPRK1 OPRM1
5 response to ethanol GO:0045471 9.83 DRD2 DRD3 OPRK1 OPRM1 SLC6A3
6 adenylate cyclase-inhibiting G-protein coupled receptor signaling pathway GO:0007193 9.82 OPRD1 OPRK1 OPRM1
7 sensory perception of pain GO:0019233 9.82 OPRD1 OPRK1 OPRM1
8 nervous system process GO:0050877 9.81 CHRNA3 CHRNA5 CHRNB3
9 visual learning GO:0008542 9.8 DBH DRD2 DRD3
10 neuromuscular synaptic transmission GO:0007274 9.77 CHRNA3 CHRNA5 CHRNB3
11 neuropeptide signaling pathway GO:0007218 9.77 OPRD1 OPRK1 OPRM1 PDYN POMC
12 regulation of sensory perception of pain GO:0051930 9.75 OPRD1 OPRK1 OPRM1
13 synaptic transmission, cholinergic GO:0007271 9.74 CHRNA3 CHRNA5 CHRNB3
14 response to radiation GO:0009314 9.73 OPRK1 OPRM1
15 positive regulation of cytokinesis GO:0032467 9.73 DRD2 DRD3
16 eating behavior GO:0042755 9.73 OPRD1 OPRK1 OPRM1
17 positive regulation of multicellular organism growth GO:0040018 9.72 DRD2 SLC6A3
18 regulation of postsynaptic membrane potential GO:0060078 9.72 CHRNA5 CHRNB3
19 associative learning GO:0008306 9.72 DBH DRD2
20 negative regulation of blood pressure GO:0045776 9.72 DRD2 DRD3
21 negative regulation of adenylate cyclase activity GO:0007194 9.72 DRD2 OPRM1
22 response to amphetamine GO:0001975 9.72 DBH DRD2 DRD3
23 excitatory postsynaptic potential GO:0060079 9.72 CHRNA3 CHRNA5 CHRNB3 DRD2 OPRM1
24 arachidonic acid secretion GO:0050482 9.71 DRD2 DRD3
25 regulation of dopamine secretion GO:0014059 9.71 DRD2 DRD3
26 dopamine receptor signaling pathway GO:0007212 9.71 DRD2 DRD3
27 synaptic transmission, dopaminergic GO:0001963 9.71 DRD2 DRD3
28 response to iron ion GO:0010039 9.71 DRD2 SLC6A3
29 behavioral response to cocaine GO:0048148 9.71 DRD2 DRD3 OPRK1
30 response to morphine GO:0043278 9.71 DRD2 DRD3 OPRK1 OPRM1
31 negative regulation of protein secretion GO:0050709 9.7 DRD2 DRD3
32 estrous cycle GO:0044849 9.7 OPRK1 OPRM1
33 dopamine metabolic process GO:0042417 9.7 DRD2 DRD3
34 positive regulation of renal sodium excretion GO:0035815 9.69 DRD2 DRD3
35 neurotransmitter biosynthetic process GO:0042136 9.69 SLC6A3 SLC6A4
36 maternal behavior GO:0042711 9.69 DBH OPRK1
37 behavioral response to ethanol GO:0048149 9.69 DBH DRD2 OPRM1
38 G-protein coupled receptor internalization GO:0002031 9.68 DRD2 DRD3
39 adenylate cyclase-inhibiting dopamine receptor signaling pathway GO:0007195 9.68 DRD2 DRD3
40 adenylate cyclase-activating dopamine receptor signaling pathway GO:0007191 9.68 DRD3 OPRM1
41 monoamine transport GO:0015844 9.67 SLC6A3 SLC6A4
42 adenohypophysis development GO:0021984 9.67 DRD2 SLC6A3
43 dopamine catabolic process GO:0042420 9.67 DBH SLC6A3
44 prepulse inhibition GO:0060134 9.67 DRD2 DRD3 SLC6A3
45 behavioral response to nicotine GO:0035095 9.66 CHRNA3 CHRNA5
46 dopamine uptake involved in synaptic transmission GO:0051583 9.65 SLC6A3 SLC6A4
47 sensory perception GO:0007600 9.65 OPRK1 OPRM1 PDYN
48 response to nicotine GO:0035094 9.65 CHRNA3 CHRNA5 CHRNB3 DRD2 SLC6A3
49 regulation of dopamine uptake involved in synaptic transmission GO:0051584 9.64 DRD2 DRD3
50 opioid receptor signaling pathway GO:0038003 9.63 OPRD1 OPRK1 OPRM1

Molecular functions related to Cocaine Dependence according to GeneCards Suite gene sharing:

(show all 19)
# Name GO ID Score Top Affiliating Genes
1 G-protein coupled receptor activity GO:0004930 9.97 DRD2 DRD3 OPRD1 OPRK1 OPRM1
2 obsolete signal transducer activity GO:0004871 9.85 DRD2 DRD3 OPRD1 OPRM1
3 ion channel activity GO:0005216 9.75 CHRNA3 CHRNA5 CHRNB3
4 peptide binding GO:0042277 9.7 OPRD1 OPRK1 OPRM1
5 drug binding GO:0008144 9.69 DRD2 DRD3 SLC6A3
6 extracellular ligand-gated ion channel activity GO:0005230 9.63 CHRNA3 CHRNA5 CHRNB3
7 neuropeptide hormone activity GO:0005184 9.58 PDYN POMC
8 ligand-gated ion channel activity GO:0015276 9.58 CHRNA3 CHRNA5 CHRNB3
9 neurotransmitter:sodium symporter activity GO:0005328 9.56 SLC6A3 SLC6A4
10 dopamine neurotransmitter receptor activity, coupled via Gi/Go GO:0001591 9.54 DRD2 DRD3
11 neuropeptide binding GO:0042923 9.54 OPRD1 OPRK1 OPRM1
12 acetylcholine binding GO:0042166 9.5 CHRNA3 CHRNA5 CHRNB3
13 monoamine transmembrane transporter activity GO:0008504 9.49 SLC6A3 SLC6A4
14 dopamine neurotransmitter receptor activity GO:0004952 9.48 DRD2 DRD3
15 dopamine:sodium symporter activity GO:0005330 9.43 SLC6A3 SLC6A4
16 acetylcholine-gated cation-selective channel activity GO:0022848 9.43 CHRNA3 CHRNA5 CHRNB3
17 acetylcholine receptor activity GO:0015464 9.33 CHRNA3 CHRNA5 CHRNB3
18 dopamine binding GO:0035240 9.13 DRD2 DRD3 SLC6A3
19 opioid receptor activity GO:0004985 8.8 OPRD1 OPRK1 OPRM1

Sources for Cocaine Dependence

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....